ImmunoGen, Inc. (NASDAQ:IMGN) VP Craig Barrows sold 37,050 shares of ImmunoGen stock in a transaction on Friday, September 15th. The shares were sold at an average price of $6.81, for a total value of $252,310.50. Following the completion of the transaction, the vice president now owns 51,100 shares of the company’s stock, valued at approximately $347,991. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Craig Barrows also recently made the following trade(s):

  • On Wednesday, September 13th, Craig Barrows sold 14,600 shares of ImmunoGen stock. The shares were sold at an average price of $6.95, for a total value of $101,470.00.

ImmunoGen, Inc. (IMGN) traded down 1.45% during midday trading on Friday, hitting $6.80. The stock had a trading volume of 5,943,687 shares. ImmunoGen, Inc. has a 52 week low of $1.51 and a 52 week high of $8.84. The company’s market capitalization is $609.26 million. The company’s 50-day moving average price is $6.58 and its 200 day moving average price is $5.18.

ImmunoGen (NASDAQ:IMGN) last announced its quarterly earnings results on Friday, July 28th. The biotechnology company reported ($0.10) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.17) by $0.07. The firm had revenue of $39.02 million during the quarter, compared to the consensus estimate of $30.59 million. During the same quarter in the previous year, the company posted ($0.53) earnings per share. The firm’s revenue was up 426.6% on a year-over-year basis. On average, analysts expect that ImmunoGen, Inc. will post ($0.74) EPS for the current year.

COPYRIGHT VIOLATION WARNING: This piece was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another website, it was illegally copied and reposted in violation of US & international copyright laws. The legal version of this piece can be read at https://www.thecerbatgem.com/2017/09/16/immunogen-inc-imgn-vp-craig-barrows-sells-37050-shares.html.

Several institutional investors and hedge funds have recently made changes to their positions in IMGN. Teachers Advisors LLC lifted its stake in shares of ImmunoGen by 10.6% in the 4th quarter. Teachers Advisors LLC now owns 209,859 shares of the biotechnology company’s stock valued at $428,000 after acquiring an additional 20,171 shares during the last quarter. Acadian Asset Management LLC bought a new position in shares of ImmunoGen in the 1st quarter valued at $117,000. Janney Montgomery Scott LLC lifted its stake in shares of ImmunoGen by 11.1% in the 1st quarter. Janney Montgomery Scott LLC now owns 58,815 shares of the biotechnology company’s stock valued at $228,000 after acquiring an additional 5,893 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in shares of ImmunoGen by 15.4% in the 1st quarter. Bank of New York Mellon Corp now owns 438,917 shares of the biotechnology company’s stock valued at $1,698,000 after acquiring an additional 58,516 shares during the last quarter. Finally, UBS Asset Management Americas Inc. lifted its stake in shares of ImmunoGen by 148.6% in the 1st quarter. UBS Asset Management Americas Inc. now owns 68,097 shares of the biotechnology company’s stock valued at $264,000 after acquiring an additional 40,700 shares during the last quarter. Institutional investors own 84.66% of the company’s stock.

IMGN has been the subject of several research analyst reports. William Blair reiterated an “outperform” rating on shares of ImmunoGen in a research report on Monday, June 26th. Royal Bank Of Canada upgraded ImmunoGen from a “sector perform” rating to an “outperform” rating and lifted their price objective for the company from $5.00 to $12.00 in a research report on Thursday, July 6th. BidaskClub downgraded ImmunoGen from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 19th. Leerink Swann reiterated a “buy” rating on shares of ImmunoGen in a research report on Tuesday, August 29th. Finally, Cantor Fitzgerald reiterated a “hold” rating on shares of ImmunoGen in a research report on Tuesday, August 29th. Two analysts have rated the stock with a sell rating, three have given a hold rating and six have given a buy rating to the company. ImmunoGen presently has an average rating of “Hold” and an average price target of $8.01.

ImmunoGen Company Profile

ImmunoGen, Inc is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. The Company is engaged in the discovery of monoclonal antibody-based anticancer therapeutics. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target.

Receive News & Stock Ratings for ImmunoGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen Inc. and related stocks with our FREE daily email newsletter.